Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer

被引：0
|
作者：
Gaulin, J. [1 ]
Kotb, R. [1 ]
Turcotte, E. [2 ]
Berard, G. [3 ]
Sawan, B. [4 ]
Schmutz, G. [5 ]
Beauregard, P. [1 ]
机构：
[1] CHU Sherbrooke, Dept Hematol & Oncol, Sherbrooke, PQ J1H 5N4, Canada
[2] CHU Sherbrooke, Dept Nucl Med, Sherbrooke, PQ J1H 5N4, Canada
[3] CHU Sherbrooke, Dept Clin Pharm, Sherbrooke, PQ J1H 5N4, Canada
[4] CHU Sherbrooke, Dept Pathol, Sherbrooke, PQ J1H 5N4, Canada
[5] CHU Sherbrooke, Dept Radiol, Sherbrooke, PQ J1H 5N4, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷 / 05期
关键词：
Colorectal cancer; bevacizumab; third-line therapy; FLUOROURACIL FAILURE; RANDOMIZED-TRIAL; PLUS IRINOTECAN; OXALIPLATIN; LEUCOVORIN; CETUXIMAB; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bevacizumab is Currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness Of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature.
引用
收藏
页码：331 / 333
页数：3
相关论文
共 50 条
  • [31] Optimizing the Treatment Sequence From Second-Line to Third-Line Therapy in Patients With Metastatic Colorectal Cancer: Discussion
    Grothey, Axel
    Prager, Gerald W.
    Yoshino, Takayuki
    Bekaii-Saab, Tanios S.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 21 - 23
  • [32] Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: Case report
    Shitara, Kohei
    Munakata, Masaki
    Muto, Osamu
    Sakata, Yuh
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (07) : 493 - 496
  • [33] The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    不详
    [J]. CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 621 - 624
  • [34] Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study
    Modest, D. P.
    Tabernero, J.
    Prager, G.
    Fakih, M.
    Ciardiello, F.
    Van Cutsem, E.
    Elez, E.
    Cruz, F.
    Wyrwicz, L.
    Stroyakovskiy, D.
    Papai, Z.
    Poureau, P. -G.
    Liposits, G.
    Cremolini, C.
    Benhadji, K.
    Bondarenko, I.
    Skanji, D.
    Roby, L.
    Amellal, N.
    Taieb, J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 157 - 158
  • [35] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoichiro Yoshida
    Takeshi Yamada
    Hirohiko Kamiyama
    Chihiro Kosugi
    Keiichiro Ishibashi
    Hiroshi Yoshida
    Hideyuki Ishida
    Satoru Yamaguchi
    Hidekazu Kuramochi
    Atsuko Fukazawa
    Hiromichi Sonoda
    Kazuhiko Yoshimatsu
    Akihisa Matsuda
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Koda
    [J]. International Journal of Clinical Oncology, 2021, 26 : 111 - 117
  • [36] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [37] The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
    Kosugi, Chihiro
    Kamiyama, Hirohiko
    Yoshida, Yoichiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Fukazawa, Atsuko
    Matsuda, Akihisa
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Narushima, Kazuo
    Shuto, Kiyohiko
    Sakamoto, Kazuhiro
    Koda, Keiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [38] Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy
    Giuliani, Jacopo
    Mantoan, Beatrice
    Mangiola, Daniela
    Muraro, Marco
    Napoli, Giuseppe
    Tommasi, Marina
    Fiorica, Francesco
    Mandara, Marta
    [J]. CLINICAL COLORECTAL CANCER, 2024, 23 (01) : 1 - 3
  • [39] Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
    Xue, Wen-Hui
    Li, Xue-Wei
    Ding, Ya-Qian
    Wu, Na
    Pei, Bei-Bei
    Ma, Xiao-Yan
    Xie, Jun
    Yang, Wen-Hui
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Efficacy of apatinib as third-line treatment of advanced colorectal cancer and prognostic analysis
    Wang, Juchao
    Sun, Qiang
    Zhao, Jian
    Li, Zengming
    Kou, Dan
    Qu, Dongxiang
    [J]. JOURNAL OF BUON, 2021, 26 (01): : 93 - 100
12345